

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Xin Lu and Nadia Godin-
Heymann

Application No. 10/581,569

Filed: January 16, 2007

Confirmation No. 3614

For: SCREENING ASSAY AND TREATMENT

Examiner: Not yet assigned

Art Unit: 1614

Attorney Reference No. 5585-68214-02

FILED VIA EFS

ON JUNE 28, 2007

REQUEST FOR CORRECTED OFFICIAL FILING RECEIPT

SUBMITTED VIA ELECTRONIC FILING SYSTEM
UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants have received the official Filing Receipt for the application referenced above, a copy of which (with requested correction handwritten thereon) is attached as Exhibit A.

The following error(s) appears on the Filing Receipt:

| ITEM IN ERROR | CORRECT INFORMATION |
|--|--|
| United Kingdom 0404242.0 filed 02/06/2004 | United Kingdom 0404242.0 filed 02/26/2004 |

Evidence of this date are attached as Exhibit B (front page of published PCT/GB2004/003899 and page 2 of the preliminary amendment filed on June 6, 2006).


Applicants request that the identified error(s) be corrected and that a new official Filing Receipt be issued.

Please call the undersigned if any further information is required.

Respectfully submitted,

KLARQUIST SPARKMAN, LLP

By


Sheree Lynn Rybak, Ph.D.
Registration No. 47,913

One World Trade Center, Suite 1600
121 S.W. Salmon Street
Portland, Oregon 97204
Telephone: (503) 595-5300
Facsimile: (503) 595-5301

cc: Docketing



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
 United States Patent and Trademark Office
 Address: COMMISSIONER FOR PATENTS
 P.O. Box 1450
 Alexandria, Virginia 22313-1450
 www.uspto.gov

Harrison Goddard
SR

| APPL NO | FILING OR 371(G) DATE | ART UNIT | FIL FEE REC'D | ATTY DOCKET NO | TOT CLMS | IND CLMS |
|------------|-----------------------|----------|---------------|----------------|----------|----------|
| 10/581,569 | 01/16/2007 | 1614 | 1640 | 5585-68214-02 | 41 | 9 |

CONFIRMATION NO. 3614

FILING RECEIPT



OC000000024402464

24197
 KLARQUIST SPARKMAN, LLP
 121 SW SALMON STREET
 SUITE 1600
 PORTLAND, OR 97204

PREVIOUSLY FILED

Date Mailed: 06/21/2007

Receipt is acknowledged of this regular Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please mail to the Commissioner for Patents P.O. Box 1450 Alexandria Va 22313-1450. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Xin Lu, London, UNITED KINGDOM;
 Nadia Godin-Heymann, Cambridge, MA;

Power of Attorney: The patent practitioners associated with Customer Number 24197.

Domestic Priority data as claimed by applicant

This application is a 371 of PCT/GB04/03899 09/13/2004
 which claims benefit of 60/554,852 03/19/2004

Foreign Applications

UNITED KINGDOM 0328106.0 12/04/2003
 UNITED KINGDOM 0404242.0 02/06/2004*


02/26/2004

If Required, Foreign Filing License Granted: 06/18/2007

The country code and number of your priority application, to be used for filing abroad under the Paris Convention, is **US10/581,569**

Projected Publication Date: 09/27/2007

Non-Publication Request: No



Early Publication Request: No

**** SMALL ENTITY ****

Title

Screening Assay and Treatment

Preliminary Class

514

PROTECTING YOUR INVENTION OUTSIDE THE UNITED STATES

Since the rights granted by a U.S. patent extend only throughout the territory of the United States and have no effect in a foreign country, an inventor who wishes patent protection in another country must apply for a patent in a specific country or in regional patent offices. Applicants may wish to consider the filing of an international application under the Patent Cooperation Treaty (PCT). An international (PCT) application generally has the same effect as a regular national patent application in each PCT-member country. The PCT process **simplifies** the filing of patent applications on the same invention in member countries, but **does not result** in a grant of "an international patent" and does not eliminate the need of applicants to file additional documents and fees in countries where patent protection is desired.

Almost every country has its own patent law, and a person desiring a patent in a particular country must make an application for patent in that country in accordance with its particular laws. Since the laws of many countries differ in various respects from the patent law of the United States, applicants are advised to seek guidance from specific foreign countries to ensure that patent rights are not lost prematurely.

Applicants also are advised that in the case of inventions made in the United States, the Director of the USPTO must issue a license before applicants can apply for a patent in a foreign country. The filing of a U.S. patent application serves as a request for a foreign filing license. The application's filing receipt contains further information and guidance as to the status of applicant's license for foreign filing.

Applicants may wish to consult the USPTO booklet, "General Information Concerning Patents" (specifically, the section entitled "Treaties and Foreign Patents") for more information on timeframes and deadlines for filing foreign patent applications. The guide is available either by contacting the USPTO Contact Center at 800-786-9199, or it can be viewed on the USPTO website at <http://www.uspto.gov/web/offices/pac/doc/general/index.html>.

For information on preventing theft of your intellectual property (patents, trademarks and copyrights), you may wish to consult the U.S. Government website, <http://www.stopfakes.gov>. Part of a Department of Commerce initiative, this website includes self-help "toolkits" giving innovators guidance on how to protect intellectual property in specific countries such as China, Korea and Mexico. For questions regarding patent enforcement issues, applicants may call the U.S. Government hotline at 1-866-999-HALT (1-866-999-4158).

LICENSE FOR FOREIGN FILING UNDER Title 35, United States Code, Section 184 Title 37, Code of Federal Regulations, 5.11 & 5.15

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The

date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Bureau of Industry and Security, Department of Commerce (15 CFR parts 730-774); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
16 June 2005 (16.06.2005)

PCT

(10) International Publication Number
WO 2005/054862 A1

- (51) International Patent Classification⁷: G01N 33/574, (74) Agent: HARRISON GODDARD FOOTER, 31 St Saviourgate, York YO1 8NQ (GB).
C07K 16/00, A61K 38/16
- (21) International Application Number: PCT/GB2004/003899
- (22) International Filing Date: 13 September 2004 (13.09.2004)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0328106.0 4 December 2003 (04.12.2003) GB
0404242.0 26 February 2004 (26.02.2004) GB
60/554,852 19 March 2004 (19.03.2004) US
- (71) Applicant (for all designated States except US): LUDWIG INSTITUTE FOR CANCER RESEARCH [CH/CH]; Postfach, CH-8024 Zurich (CH).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): LI, Xiu [CN/GB]; Ludwig Institute for Cancer Research, Imperial College London, Faculty of Medicine, St Mary's Campus, Norfolk Place, London W2 1PG (GB). GODIN-HEYMANN, Nadia [CH/US]; 8 Plymton Street, Apt. 47, Cambridge, MA 02138 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: SCREENING ASSAY AND TREATMENT

(57) Abstract: The invention relates to screening assays for the identification of agents which modulate the activity of polypeptides which affect the apoptotic activity of the tumour suppressor protein p53 and including gene therapy vectors comprising p53 and antibodies that bind phosphorylated epitopes.

WO 2005/054862 A1



Amendments to the Specification

On page 1, after the title, please insert the following paragraph and heading:

PRIORITY CLAIM

This is the U.S. National Stage of International Application No. PCT/GB2004/003899, filed September 13, 2004 (published in English under PCT Article 21(2)), which in turn claims the benefit of Great Britain Application No. 0328106.0, filed December 4, 2003, Great Britain Application No. 0404242.0, filed February 26, 2004, and U.S. Provisional Application No. 60/554,852, filed March 19, 2004.

Please replace the paragraphs beginning on page 24, line 19, with the following re-written paragraphs:

--Figure 17a is the ASPP1 nucleic acid sequence (SEQ ID NO: 1); Figure 17b is the ASPP2 nucleic acid sequence (SEQ ID NO: 2); Figure 17c is the ASPP1 protein sequence (SEQ ID NO: 3); Figure 17d is the ASPP2 protein sequence (SEQ ID NO: 4);

Figure 18a is the H-Ras wild-type nucleic acid sequence (SEQ ID NO: 5); Figure 18b is the H-Ras protein sequence (SEQ ID NO: 6); Figure 18c is the H-Ras oncogenic nucleic acid sequence (SEQ ID NO: 7); Figure 18d is the H-Ras oncogenic protein sequence (SEQ ID NO: 8); Figure 18e is the K Ras wild-type nucleic acid sequence (SEQ ID NO: 9); Figure 18f is the wild -type K-Ras protein sequence (SEQ ID NO: 10); Figure 18g is the K-Ras oncogenic nucleic acid sequence (SEQ ID NO: 11); and Figure 18h is the K-Ras oncogenic protein sequence (SEQ ID NO: 12);

Figure 19a is the MAPK nucleic acid sequence (SEQ ID NO: 13); Figure 19b is the MAPK protein sequence (SEQ ID NO: 14);

Figure 20a is the PKA nucleic acid sequence (SEQ ID NO: 15); Figure 20b is the PKA protein sequence (SEQ ID NO: 16);